2025
Mediators of Racial Inequities in Non‐Small Cell Lung Cancer Care
Hamid S, Lee D, Herrin J, Yu J, Pollack C, Dean L, Gaddy J, Oladele C, Feder S, Canavan M, Nunez-Smith M, Soulos P, Gross C. Mediators of Racial Inequities in Non‐Small Cell Lung Cancer Care. Cancer Medicine 2025, 14: e70757. PMID: 40052387, DOI: 10.1002/cam4.70757.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancer carePhase of careSocioeconomic statusNon-small cell lung cancerIndividual-level socioeconomic statusNeighborhood-level socioeconomic statusMedicare-Medicaid dual eligibilityWhite patientsHealth care accessLung cancer careNon-Hispanic blacksIndirect effects of mediatorsDiagnosis stageStage-appropriate treatmentTwo-year survivalCancer careCare accessEffects of raceOptimal careDual eligiblesCareStructural racismRacial inequalityBlack patientsInadequate evaluation
2024
Comparative Effectiveness of SBRT
Shen J, Sritharan D, Yu J, Aneja S. Comparative Effectiveness of SBRT. 2024, 455-467. DOI: 10.1007/978-3-031-67743-4_33.Peer-Reviewed Original ResearchStereotactic body radiation therapyEffect of stereotactic body radiation therapyAlternative to other treatment modalitiesStereotactic body radiation therapy treatmentLong-term follow-up of patientsFollow-up of patientsLong-term follow-upTreatment of brainOligometastatic diseaseRadiation therapyTreatment of cancerRetrospective seriesTreatment modalitiesRenal cancerCost-effectiveness studiesDatabase analysisCancerTreatmentProstateTherapyInappropriate Denials for Radiation Therapy in Medicare Advantage Plans
Pasetsky J, Bhatt K, Kachnic L, Yu J, Horowitz D. Inappropriate Denials for Radiation Therapy in Medicare Advantage Plans. International Journal Of Radiation Oncology • Biology • Physics 2024, 121: 871-874. PMID: 39551102, DOI: 10.1016/j.ijrobp.2024.11.063.Peer-Reviewed Original ResearchConceptsIntensity-modulated RTRadiation therapyStereotactic body radiation therapyHealth servicesMedicare Advantage plansMedicare-eligible patientsChi-square testRadiation oncologistsProstate cancerTreatment modalitiesBreast cancerCancer treatmentTherapyCancerRT servicesPolicy changesMedicaid Services websiteCoverage guidelinesDenial ratesMedical specialtiesCenters for Medicare & Medicaid Services websiteTreatmentDenialBrachytherapyProstateRadiation Therapy for the Treatment of Osteoarthritis
Yu J, Grew D, Spraker M, Beckta J, Shah C, Brower J. Radiation Therapy for the Treatment of Osteoarthritis. Practical Radiation Oncology 2024, 15: 19-24. PMID: 39503700, DOI: 10.1016/j.prro.2024.09.003.Peer-Reviewed Original ResearchConceptsRadiation therapyAssessment of treatment responseTreatment of osteoarthritisMedically refractory diseaseNonsteroidal anti-inflammatory drugsNoninvasive treatment optionCause of painCyclooxygenase-2 inhibitorsIntra-articular corticosteroid therapyAnti-inflammatory drugsCorticosteroid therapyRefractory diseaseTreatment responseTreatment optionsClinical evidenceOlder patientsTherapyCyclooxygenase-2PatientsTraditional treatmentPhysical therapyPainTreatmentOsteoarthritisTechnical considerationsInappropriate Denials for Radiation Therapy in Medicare Advantage Plans: An Independent Review Entity and Call for Action
Pasetsky J, Kachnic L, Yu J, Horowitz D. Inappropriate Denials for Radiation Therapy in Medicare Advantage Plans: An Independent Review Entity and Call for Action. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s127. DOI: 10.1016/j.ijrobp.2024.07.230.Peer-Reviewed Original ResearchRadiation therapyCenters for Medicare & Medicaid ServicesTraditional MedicareMA plansLife-saving cancer treatmentStatistically significant higher rateGrowing body of literatureBody of literatureMA star ratingsSignificantly higher ratesMedicare AdvantageUnfavorable decisionsHospice careStarsImprove accessCancer treatmentDenialRT servicesServicesAppealStar ratingsGrowing bodyCenters for Medicare & Medicaid Services websiteMedicare Advantage plansTherapyTestosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial
Moningi S, Nguyen P, Rathkopf D, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Shin K, Taplin M, Kollmeier M, Hoffman K. Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e563-e564. DOI: 10.1016/j.ijrobp.2024.07.1247.Peer-Reviewed Original ResearchMonths of GnRH agonistTestosterone recoveryGnRH agonistAssociated with lackClinically meaningful changeBaseline testosteroneAssociated with testosterone recoveryMedian follow-upEvaluated prior to treatmentTreatment groupsTrial randomized patientsHormonal functionPatient-reported health-related quality of lifeLog-rank testCompletion of treatmentMultivariate logistic regressionWilcoxon rank-sumPatient-reported HRQoL.Salvage radiationGleason scoreAbiraterone acetateHigher PSARecovery 1 yearRandomized patientsHealth-related quality of lifeLong-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy
Hoffman K, Nguyen P, Rathkopf D, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Lee K, Kibel A, Taplin M, Kollmeier M. Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s54. DOI: 10.1016/j.ijrobp.2024.07.088.Peer-Reviewed Original ResearchAbiraterone acetate plus prednisoneMonths of GnRH agonistAcetate plus prednisonePatient-reported health-related quality of lifeEPIC-26Hormonal functionHealth-related quality of lifeGnRH agonistTreatment armsTreatment to 1 yearQuality of lifeMental statusMetastasis-free survivalBaseline to endCompletion of treatmentSalvage radiationSalvage radiotherapyOncological outcomesRadical prostatectomyClinically meaningful differencesSaint Louis University Mental Status ExamNear baselineClinically meaningful declineT-scoreHormonal domainsCancer care and the coconut tree: all in which it lives, and has come before
Yu J. Cancer care and the coconut tree: all in which it lives, and has come before. JNCI Cancer Spectrum 2024, 8: pkae083. PMID: 39428118, PMCID: PMC11491160, DOI: 10.1093/jncics/pkae083.Peer-Reviewed Original ResearchPeer-to-Peer Phone Calls and Letters Appealing Insurance Denials of Service: Practical Tips and Resources
Pasetsky J, Garcia-Young J, Beatley E, Yu J. Peer-to-Peer Phone Calls and Letters Appealing Insurance Denials of Service: Practical Tips and Resources. Practical Radiation Oncology 2024, 14: e434-e437. PMID: 39089624, DOI: 10.1016/j.prro.2024.06.015.Peer-Reviewed Original ResearchReply to O. Saifi et al
Yu J, DeStephano D, Horowitz D, Gross C, Cheng S. Reply to O. Saifi et al. Journal Of Clinical Oncology 2024, 42: 3763-3764. PMID: 39079081, DOI: 10.1200/jco-24-01228.Peer-Reviewed Original ResearchIn Reply to Beckta
Yu J, Luh J, Mantz C. In Reply to Beckta. Practical Radiation Oncology 2024, 14: 355-356. PMID: 38942571, DOI: 10.1016/j.prro.2024.04.004.Peer-Reviewed Original ResearchThe IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas
Kinslow C, Roy S, Iwamoto F, Brown P, DeStephano D, Canoll P, Qureshi S, Gallito M, Sisti M, Bruce J, Horowitz D, Kachnic L, Neugut A, Yu J, Mehta M, Cheng S, Wang T. The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas. Neuro-Oncology 2024, 26: 1839-1849. PMID: 38943513, PMCID: PMC11449043, DOI: 10.1093/neuonc/noae102.Peer-Reviewed Original ResearchProgression-free survivalIDH-mutant gliomasLow grade gliomasOverall survivalIDH-wtAlkylating chemotherapyGrade gliomasChemotherapy improves overall survivalMeta-analysis of randomized clinical trialsEffects of alkylating chemotherapyCompared to radiotherapyIDH-mutant tumorsWorld Health OrganizationIDH-wt glioblastomaIDH-wt gliomasMeta-analysisDiagnosis of glioblastomaIDH-wt tumorsIDH-wild typeRandomized clinical trialsRandom-effects modelMagnitude of benefitGlioblastoma trialsAnaplastic morphologyOS benefitUpdated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer
Yu J, DeStephano D, Jeffers B, Horowitz D, Soulos P, Gross C, Cheng S. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. Journal Of Clinical Oncology 2024, 42: 1943-1952. PMID: 38507655, DOI: 10.1200/jco.23.01604.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyProton beam therapyGU toxicityProstate cancerGI toxicityBenefits of proton beam therapyIntensity-modulated radiation therapy patientsPBT patientsLocalized prostate cancerTreatment-related toxicityComparison of GIStatistically significant differenceRadiation therapyBeam therapySEER-MedicareToxicity of protonProcedure codesComparative effectiveness studiesObservational studyPatientsSignificant differenceCancerMonthsComparing GIProstatePractical Considerations for the Treatment of an Adrenal Metastasis With Stereotactic Body Radiation Therapy
Yu J, Grew D, Sculley E, Hitchcock K, Kim M, Lo S. Practical Considerations for the Treatment of an Adrenal Metastasis With Stereotactic Body Radiation Therapy. Practical Radiation Oncology 2024, 14: 338-342. PMID: 38493984, DOI: 10.1016/j.prro.2024.02.003.Peer-Reviewed Original ResearchThe Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma
Lee A, Runcie K, Yu J. The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma. Kidney Cancer 2024, 8: 45-50. DOI: 10.3233/kca-230020.Peer-Reviewed Original ResearchStereotactic body radiotherapyTreatment of renal cell carcinomaRenal cell carcinomaCell carcinomaCombination of stereotactic body radiotherapyUse of stereotactic body radiotherapyNovel systemic agentsTargeted radiation therapyTreatment of RCCRadiation therapySystemic agentsCarcinomaTreatmentRCCRadiotherapyRadiation technologyIncreased useTherapyIntensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).
Posadas E, Gay H, Rodgers J, Morgan T, Xiao Y, Yu J, Michalski J, Bouchard M, Desai N, Funk R, Boike T, Jurgens D, Wong A, Shen X, Miyawaki L, Bland C, Hairston J, Sandler H, Pugh S, Feng F. Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL). Journal Of Clinical Oncology 2024, 42: 131-131. DOI: 10.1200/jco.2024.42.4_suppl.131.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression free survivalSalvage radiotherapyHigh-risk featuresBiochemical relapseHigh-risk patientsRadical prostatectomyLHRH analogsDecreased lymphocytesAndrogen receptorMonths of androgen deprivation therapyGrade 3 adverse eventsProgression free survival benefitStandard androgen deprivation therapyMedian follow-up timeGrade 4 AEsPara-aortic radiotherapyProstate cancer patientsEnzalutamide armGleason 9Salvage radiationDeprivation therapyNodal involvementFree survivalRT boostPatient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).
Hoffman K, Nguyen P, Rathkopf D, Zurita A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, McKay R, Rose B, Shin K, Kibel A, Taplin M, Kollmeier M. Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP). Journal Of Clinical Oncology 2024, 42: 260-260. DOI: 10.1200/jco.2024.42.4_suppl.260.Peer-Reviewed Original ResearchAbiraterone acetate plus prednisoneSaint Louis University Mental Status ExamMonths of GnRH agonistPatient-reported health-related quality of lifeEPIC-26Radical prostatectomyHealth-related quality of lifeGnRH agonistTreatment armsHormonal functionPROMIS FatigueTreatment to 1 yearQuality of lifeAcetate plus prednisoneMental statusMetastasis-free survivalBaseline to endMental status examStandardized T scoresMild neurocognitive disorderCompletion of treatmentSalvage radiationSalvage radiotherapyOncological outcomesClinically meaningful differencesPractical Implications of the American Society for Radiation Oncology Radiation Oncology Case Rate Program Proposal for Radiation Oncologists
Yu J, Luh J, Mantz C. Practical Implications of the American Society for Radiation Oncology Radiation Oncology Case Rate Program Proposal for Radiation Oncologists. Practical Radiation Oncology 2024, 14: 196-199. PMID: 38237890, DOI: 10.1016/j.prro.2023.12.010.Peer-Reviewed Original ResearchBuilding on the past and creating a brave future: a message from the incoming editor in chief
Yu J. Building on the past and creating a brave future: a message from the incoming editor in chief. JNCI Cancer Spectrum 2024, 8: pkad096. PMID: 38185809, PMCID: PMC10868384, DOI: 10.1093/jncics/pkad096.Peer-Reviewed Original ResearchGo for Broke!
Yu J, Kim J. Go for Broke! International Journal Of Radiation Oncology • Biology • Physics 2024, 118: 11-12. PMID: 38049219, DOI: 10.1016/j.ijrobp.2023.10.011.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply